Evaxion Biotech A/S (EVAX) News
Filter EVAX News Items
EVAX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EVAX News Highlights
- EVAX's 30 day story count now stands at 3.
- Over the past 2 days, the trend for EVAX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about EVAX are ARM, DEC and GHI.
Latest EVAX News From Around the Web
Below are the latest news stories about EVAXION BIOTECH A that investors may wish to consider to help them evaluate EVAX as an investment opportunity.
Evaxion Biotech Announces Closing of Private PlacementMSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, is contributing with some 25% of the total offering amount Company’s management and board of directors with significant participation in the total offering COPENHAGEN, Denmark, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced |
EVAX Stock Earnings: Evaxion Biotech Misses EPS for Q3 2023EVAX stock results show that Evaxion Biotech missed analyst estimates for earnings per share the third quarter of 2023. |
Evaxion Announces Business Update and Third Quarter 2023 Financial ResultsThe Evaxion Three-Pronged Strategy Evaxion Announces Business Update and Third Quarter 2023 Financial Results Christian Kanstrup joined Evaxion as Chief Executive Officer in SeptemberEvaxion has launched its refined strategy with an increased focus on value realization via partnerships based upon the AI-Immunology™ platformSolid progress has already been seen on the refined strategy with two partnerships announced in Q3 and proof-of-principle for Evaxion’s proprietary responder model based upon |
Evaxion Biotech Announces Private Placement FinancingMSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, is contributing with some 25% of the total offering amount Company’s management and board of directors with significant participation in the total offering COPENHAGEN, Denmark, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is pleased to a |
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine ConceptProof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cancers by targeting a novel class of antigensBroad Applicability – The vaccine concept holds tremendous potential, offering broad applicability and promising benefits for patients with hematological malignancies COPENHAGEN, Denmark, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company spec |
Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer ImmunotherapyEvaxion today presents a novel AI model designed to predict patient responses to standard-of-care cancer immunotherapyThe model demonstrates promising potential for improving patient outcomes, reducing healthcare costs and is scalable for broader applicationsEvaxion will pursue a partnership-based approach towards a commercial offering COPENHAGEN, Denmark, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializ |
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan KhattakEVX-01 is Evaxion’s lead clinical asset based upon its AI-Immunology™ platform and has recently published a phase 2 clinical update confirming former phase 1 resultsPrincipal investigator Professor Adnan Khattak will walk us through this study’s encouraging results and explain its potential for revolutionizing cancer treatment COPENHAGEN, Denmark, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in th |
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01Initial EVX-01 Phase 2 data confirms the strong Phase 1 results After undergoing EVX-01 treatment, a significant and continuous tumor reduction was observed in a metastatic melanoma patient with initial progressive disease COPENHAGEN, Denmark, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in the development of AI-Immunology™ powered vaccines, is pleased to announce initial results from the EVX-01 P |
New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be PresentedData from Evaxion’s two personalized cancer vaccine clinical trials to be presented at the annual meeting of the Society for Immunotherapy of Cancer (SITC)These new sets of clinical data further strengthen Evaxion’s position as a pioneering cancer vaccine company COPENHAGEN, Denmark, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™-powered vaccines, is proud to announce th |
Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyCOPENHAGEN, Denmark, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, announced today that the Company received a letter (the “Notification Letter”) on September 29, 2023 from the Listings Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Compa |